本文關(guān)鍵詞： miR-b 子宮內(nèi)膜癌 HOXA 細(xì)胞增殖　出處：《廣東醫(yī)學(xué)》2017年09期 　論文類(lèi)型：期刊論文

【摘要】：目的探討miR-135b對(duì)子宮內(nèi)膜癌中HOXA10基因表達(dá)的調(diào)控作用。方法 RT-PCR方法檢測(cè)28例子宮內(nèi)膜癌組織及相應(yīng)癌旁組織中miR-135b及HOXA10的表達(dá);用miR-135b模擬物及抑制物轉(zhuǎn)染RL-952子宮內(nèi)膜癌細(xì)胞株,RT-PCR檢測(cè)轉(zhuǎn)染效果并檢測(cè)FOXO1 mRNA的變化,劃痕實(shí)驗(yàn)檢測(cè)轉(zhuǎn)染后對(duì)細(xì)胞遷移的影響,流式細(xì)胞技術(shù)檢測(cè)轉(zhuǎn)染對(duì)細(xì)胞增殖的影響,Western blot檢測(cè)HOXA10蛋白的變化。結(jié)果 miR-135b在子宮內(nèi)膜癌組織中較對(duì)應(yīng)的癌旁組織表達(dá)升高(P0.05),HOXA10則降低(P0.05),經(jīng)miR-135b模擬物轉(zhuǎn)染后,子宮內(nèi)膜癌細(xì)胞中HOXA10 mRNA和蛋白的表達(dá)水平下降(P0.05);經(jīng)miR-135b抑制物轉(zhuǎn)染后,子宮內(nèi)膜癌細(xì)胞中HOXA10 mRNA和蛋白的表達(dá)水平升高(P0.05);miR-135b能促進(jìn)子宮內(nèi)膜癌細(xì)胞的增殖(P0.05)。結(jié)論 miR-135b在子宮內(nèi)膜癌發(fā)生發(fā)展中有一定作用,子宮內(nèi)膜中HOXA10的異常表達(dá)受miR-135b的調(diào)控。
[Abstract]:Objective to investigate the effect of miR-135b on the expression of HOXA10 gene in endometrial carcinoma. RT-PCR method was used to detect the expression of miR-135b and HOXA10 in 28 cases of endometrial carcinoma and its adjacent tissues. The transfection effect and FOXO1 mRNA of RL-952 endometrial carcinoma cell line were detected by RT-PCR with miR-135b mimic and inhibitor. The effect of transfection on cell migration was detected by scratch test, and the effect of transfection on cell proliferation was detected by flow cytometry. Western blot was used to detect the changes of HOXA10 protein. Results the expression of miR-135b in endometrial carcinoma tissues was higher than that in the corresponding adjacent tissues (P0.05). The expression of HOXA10 mRNA and protein in endometrial cancer cells decreased after transfection with miR-135b mimics. After transfection with miR-135b inhibitor, the expression of HOXA10 mRNA and protein increased in endometrial carcinoma cells. MiR-135b can promote the proliferation of endometrial carcinoma cells. Conclusion miR-135b may play a role in the development of endometrial carcinoma. Abnormal expression of HOXA10 in endometrium is regulated by miR-135b.
【作者單位】： 南方醫(yī)科大學(xué)南方醫(yī)院婦產(chǎn)科;廣東省婦幼保健院婦產(chǎn)科;
【基金】：廣東省科技計(jì)劃項(xiàng)目(編號(hào):2014A020212628)
【分類(lèi)號(hào)】：R737.33
【正文快照】： 子宮內(nèi)膜癌是女性生殖系統(tǒng)常見(jiàn)的惡性腫瘤,發(fā)病機(jī)制尚未完全明確,研究認(rèn)為在子宮內(nèi)膜增生的過(guò)程中,基因改變導(dǎo)致了子宮內(nèi)膜惡變[1]。子宮內(nèi)膜癌惡性程度較高、侵襲性強(qiáng),預(yù)后較差,對(duì)于早期發(fā)現(xiàn)在原位的患者,5年生存率可達(dá)90%,晚期發(fā)生遠(yuǎn)處轉(zhuǎn)移的患者,5年生存率低于20%[2]。在過(guò)

【相似文獻(xiàn)】

相關(guān)碩士學(xué)位論文 前1條

1 樂(lè)珍;miR-135b在子宮內(nèi)膜癌發(fā)生發(fā)展中的作用和機(jī)制的初步探討[D];南方醫(yī)科大學(xué);2016年

，

本文編號(hào)：1464109